Bionet (1784) reported revenue of NT$94.4 million for Oct 2026, -12.0% year on year and -2.7% from the previous month. Revenue for Jan–Oct 2026 was NT$1.07 billion (+7.4% year on year).
In Oct 2026, it ranked No. 80 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$94.4 million | -12.0% | -2.7% |
| Sep 2026 | NT$97 million | +7.4% | -11.0% |
| Aug 2026 | NT$109.1 million | +14.4% | -9.9% |
| Jul 2026 | NT$121 million | +7.8% | +9.0% |
| Jun 2026 | NT$111.1 million | +5.4% | +0.2% |
| May 2026 | NT$110.8 million | +15.0% | -4.9% |
| Apr 2026 | NT$116.5 million | +13.5% | -8.4% |
| Mar 2026 | NT$127.2 million | +14.7% | +57.6% |
| Feb 2026 | NT$80.7 million | -13.6% | -24.4% |
| Jan 2026 | NT$106.8 million | +23.6% | -27.0% |
| Dec 2025 | NT$146.4 million | +14.4% | +63.1% |
| Nov 2025 | NT$89.8 million | -15.7% | -16.3% |
| Oct 2025 | NT$107.3 million | +11.4% | +18.7% |
| Sep 2025 | NT$90.3 million | -0.7% | -5.2% |
| Aug 2025 | NT$95.4 million | -8.3% | -15.1% |
| Jul 2025 | NT$112.3 million | +4.8% | +6.5% |
| Jun 2025 | NT$105.4 million | +15.7% | +9.4% |
| May 2025 | NT$96.4 million | -4.2% | -6.1% |
| Apr 2025 | NT$102.6 million | +1.5% | -7.5% |
| Mar 2025 | NT$110.9 million | +4.0% | +18.7% |
| Feb 2025 | NT$93.4 million | +6.9% | +8.1% |
| Jan 2025 | NT$86.5 million | -15.6% | -32.5% |
| Dec 2024 | NT$128 million | +24.3% | +20.3% |
| Nov 2024 | NT$106.4 million | +20.6% | +10.5% |
| Oct 2024 | NT$96.3 million | +3.2% | +5.9% |
Jan–Oct 2026 cumulative: NT$1.07 billion (+7.4% YoY)
Other Biotech & Medical companies
Compare with peers: Bionet vs PEC / Bionet vs Lotus Pharm / Bionet vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16